Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Paroxetine IR Tablets in Healthy Chinese Participants
NCT03329573Phase 1Completed
- Sponsor
- GSK
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paroxetine in anxiety disorders (4 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time at 96 hours, Area Under the Concentration-time Curve From Administration Extrapolated to the Last Time of Quantifiable Concentration at 96 hours and 1 more. Started May 2018; status: completed.
02
Drugs
paroxetine
03
Conditions
anxiety disorders
Beyond the preview
Go deeper on NCT03329573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329573.